Renaissance Technologies (RenTech)'s ACAD Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 1.53 M shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $40.94 M, representing 0.06% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ACAD, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 823,333 shares. Largest reduction occurred in Q1 2020, reducing 670,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +83,063 | Add 5.73% | 1.53 M | $26.71 |
| Q3 2025 | -98,199 | Reduce 6.34% | 1.45 M | $21.34 |
| Q2 2025 | +70,699 | Add 4.79% | 1.55 M | $21.57 |
| Q1 2025 | +250,500 | Add 20.42% | 1.48 M | $16.61 |
| Q4 2024 | +823,333 | Add 204.20% | 1.23 M | $18.35 |
| Q3 2024 | -72,800 | Reduce 15.29% | 403,200 | $15.38 |
| Q2 2024 | -97,800 | Reduce 17.04% | 476,000 | $16.25 |
| Q1 2024 | +389,800 | Add 211.85% | 573,800 | $18.49 |
| Q4 2023 | +184,000 | New Buy | 184,000 | $31.31 |
| Q3 2023 | -130,800 | Sold Out | 0 | $0.00 |
| Q2 2023 | +13,000 | Add 11.04% | 130,800 | $0.02 |
| Q1 2023 | -197,900 | Reduce 62.69% | 117,800 | $0.02 |
| Q4 2022 | +278,000 | Add 737.40% | 315,700 | $0.02 |
| Q3 2022 | +37,700 | New Buy | 37,700 | $16.37 |
| Q2 2022 | -14,500 | Sold Out | 0 | $0.00 |
| Q1 2022 | +14,500 | New Buy | 14,500 | $24.21 |
| Q2 2021 | -581,000 | Sold Out | 0 | $0.00 |
| Q1 2021 | +398,600 | Add 218.53% | 581,000 | $25.80 |
| Q4 2020 | -87,100 | Reduce 32.32% | 182,400 | $53.46 |
| Q3 2020 | +157,300 | Add 140.20% | 269,500 | $41.25 |
| Q2 2020 | +51,400 | Add 84.54% | 112,200 | $48.47 |
| Q1 2020 | -670,200 | Reduce 91.68% | 60,800 | $42.25 |
| Q4 2019 | +645,200 | Add 751.98% | 731,000 | $42.78 |
| Q3 2019 | +85,800 | New Buy | 85,800 | $35.99 |
| Q1 2019 | -597,800 | Sold Out | 0 | $0.00 |
| Q4 2018 | +425,500 | Add 246.95% | 597,800 | $16.17 |
| Q3 2018 | -50,900 | Reduce 22.80% | 172,300 | $20.76 |
| Q2 2018 | +223,200 | New Buy | 223,200 | $15.27 |
Renaissance Technologies (RenTech)'s ACADIA Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q2 2018, acquiring 223,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held ACADIA Pharmaceuticals Inc. (ACAD) for 28 quarters since Q2 2018.
Renaissance Technologies (RenTech)'s largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q4 2024, adding 1,226,533 shares worth $22.51 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 1,532,596 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $40.94 M.
As of the Q4 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.06% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 1,547,732 shares, as reported at the end of Q2 2025.